Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Methylene Blue in the Microhemodynamics of Septic Patients
Sponsor: Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva
Summary
The aim of the study is to evaluate the viability and feasibility of its protocol in order to conduct a larger clinical trial to assess whether methylene blue can improve patient-centered clinical outcomes such as mortality or length of hospital stay in septic shock patients.
Official title: Evaluation of Early Methylene Blue in the Microhemodynamics of Septic Patients: a Feasibility Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-01-09
Completion Date
2026-12-31
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Methylene blue infusion
Methylene blue at a dose of 100mg (diluted in 100ml of 5% dextrose solution) in continuous infusion for 06 hours per day, for 03 days, plus standard treatment according to international guidelines for the management of sepsis and septic shock. The 03 consecutive MB infusions, each lasting 06 hours, will be performed every 24 hours, starting from randomization: the first infusion at T0, the second at T24, and the third at T48, considering T0 the moment after the patient randomization into the study. The interruption of the protocol will be recommended if vasopressors are completely discontinued during the three days of methylene blue infusion. The attending physician may discontinue methylene blue treatment if judges necessary. Similarly, interruption may occur if the family or patient request.
Locations (1)
Irmandade da Santa Casa de Misericórdia de Curitiba
Curitiba, Paraná, Brazil